Squamous cell carcinoma of the head and neck (SCCHN) is a prevalent disease both in the
United States and worldwide with an overall poor prognosis, in part due to limited activity of …

Background We evaluated combined targeting with cetuximab, an anti-epidermal growth
factor receptor (EGFR) monoclonal antibody, and bevacizumab, an anti-vascular endothelial …

6033 Background: Pembrolizumab (a humanized monoclonal antibody blocking
programmed death receptor-1 [PD-1]), and cetuximab (a chimeric monoclonal antibody …

In patients with squamous cell carcinoma of the head and neck (SCCHN), tumor recurrence,
secondary tumors, and comorbidities contribute to therapy failure, and treatment approaches …

PURPOSE: To report our experience with a prospective protocol of external beam
reirradiation (Re-RT) combined with cetuximab for patients with inoperable, recurrent …

Background Angiogenesis is a hallmark of head and neck squamous cell carcinoma
(HNSCC), and a mechanism of resistance to EGFR inhibition. We investigated the safety …

Despite extensive research in squamous cell carcinoma of the head and neck (SCCHN), the
epidermal growth factor receptor (EGFR) remains the only nonchemotherapeutic molecular …

Background: Monalizumab (Mona) is an immune checkpoint inhibitor targeting NKG2A
receptors expressed on tumor-infiltrating CD8 T and Natural Killer (NK cells). The NKG2A …

Background After the introduction of ICI treatment, data about feasibility and activity of a
cetuximab-containing first-line therapy in patients with recurrent and/or metastatic head and …

This paper presents a summary of the evidence review group (ERG) report into the clinical
effectiveness and cost-effectiveness of cetuximab for recurrent and/or metastatic squamous …